Skip to main content

  • Getting Rid of Co-Pays Doesn't Fix Antiplatelet Nonadherence

    • Posted: 01/10/2019
    • Author:

      Nicole Lou, Reporter, MedPage Today/CRTonline.org

    • 2019News Articles

    No better trial outcomes with vouchers for P2Y12 inhibitors either

    Taking away the cost barrier improved post-MI adherence to P2Y12 inhibitor therapy only slightly in the randomized ARTEMIS trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details